DK3592355T3 - KX2-391/KX-01 til anvendelse i behandling af aktinisk keratose - Google Patents

KX2-391/KX-01 til anvendelse i behandling af aktinisk keratose

Info

Publication number
DK3592355T3
DK3592355T3 DK18764980.1T DK18764980T DK3592355T3 DK 3592355 T3 DK3592355 T3 DK 3592355T3 DK 18764980 T DK18764980 T DK 18764980T DK 3592355 T3 DK3592355 T3 DK 3592355T3
Authority
DK
Denmark
Prior art keywords
treatment
actinic keratosis
keratosis
actinic
Prior art date
Application number
DK18764980.1T
Other languages
English (en)
Inventor
Min-Fun Rudolf Kwan
E Douglas Kramer
David Lawrence Cutler
Jane Fang
Johnson Yiu-Nam Lau
Original Assignee
Atnx Spv Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3592355(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv Llc filed Critical Atnx Spv Llc
Application granted granted Critical
Publication of DK3592355T3 publication Critical patent/DK3592355T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18764980.1T 2017-03-10 2018-03-12 KX2-391/KX-01 til anvendelse i behandling af aktinisk keratose DK3592355T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
PCT/US2018/021929 WO2018165647A1 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis

Publications (1)

Publication Number Publication Date
DK3592355T3 true DK3592355T3 (da) 2026-02-16

Family

ID=63446658

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18764980.1T DK3592355T3 (da) 2017-03-10 2018-03-12 KX2-391/KX-01 til anvendelse i behandling af aktinisk keratose

Country Status (23)

Country Link
US (3) US10617693B2 (da)
EP (2) EP3592355B1 (da)
JP (3) JP7502863B2 (da)
KR (2) KR20240090837A (da)
CN (1) CN110891575A (da)
AU (2) AU2018231144B2 (da)
BR (1) BR112019018687A2 (da)
CA (1) CA3055938A1 (da)
DK (1) DK3592355T3 (da)
ES (1) ES3060528T3 (da)
FI (1) FI3592355T3 (da)
HR (1) HRP20260155T1 (da)
IL (1) IL269182B2 (da)
LT (1) LT3592355T (da)
MX (2) MX387658B (da)
NZ (1) NZ757105A (da)
PL (1) PL3592355T3 (da)
PT (1) PT3592355T (da)
RS (1) RS67713B1 (da)
SI (1) SI3592355T1 (da)
TW (1) TWI841523B (da)
WO (1) WO2018165647A1 (da)
ZA (1) ZA202100106B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
FI3592355T3 (fi) * 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa
IL326637A (en) 2017-09-07 2026-04-01 Atnx Spv Llc Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
CN117599189A (zh) * 2018-03-07 2024-02-27 慧源Spv公司 用于治疗过度增殖性皮肤障碍的组合物和方法
JP7296945B2 (ja) * 2018-03-28 2023-06-23 テルモ株式会社 医療デバイス
WO2020247706A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
JP2024506240A (ja) * 2021-01-21 2024-02-13 サーナオミクス インコーポレイテッド 皮膚がんの治療のための組成物および方法
WO2025077886A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
ES2382068T3 (es) 2004-12-28 2012-06-05 Kinex Pharmaceuticals, Llc Composiciones y métodos para tratar trastornos de proliferación celular
JP5564251B2 (ja) 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
WO2008030892A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
WO2008144045A1 (en) 2007-05-17 2008-11-27 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
SI2378876T1 (sl) * 2008-12-19 2019-05-31 Medicis Pharmaceutical Corporation Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
FI3592355T3 (fi) * 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa

Also Published As

Publication number Publication date
CN110891575A (zh) 2020-03-17
KR20190141661A (ko) 2019-12-24
IL269182B2 (en) 2023-11-01
MX2021013354A (es) 2021-11-18
US20200197405A1 (en) 2020-06-25
KR20240090837A (ko) 2024-06-21
AU2018231144B2 (en) 2023-12-21
JP2023015269A (ja) 2023-01-31
AU2024201828A1 (en) 2024-05-02
LT3592355T (lt) 2026-02-25
JP2025029010A (ja) 2025-03-05
US20180256589A1 (en) 2018-09-13
JP2020510042A (ja) 2020-04-02
HRP20260155T1 (hr) 2026-03-27
PT3592355T (pt) 2026-02-03
RU2019131757A3 (da) 2021-05-31
TWI841523B (zh) 2024-05-11
EP4659740A3 (en) 2026-02-18
EP3592355A1 (en) 2020-01-15
US11497750B2 (en) 2022-11-15
TW201842913A (zh) 2018-12-16
US10617693B2 (en) 2020-04-14
EP3592355B1 (en) 2025-12-10
NZ757105A (en) 2026-02-27
RS67713B1 (sr) 2026-02-27
AU2024201828B2 (en) 2026-02-19
US20230172942A1 (en) 2023-06-08
SI3592355T1 (sl) 2026-04-30
BR112019018687A2 (pt) 2020-04-07
EP4659740A2 (en) 2025-12-10
WO2018165647A1 (en) 2018-09-13
MX2019010707A (es) 2020-01-15
FI3592355T3 (fi) 2026-02-13
AU2018231144A1 (en) 2019-10-03
ZA202100106B (en) 2022-08-31
IL269182A (en) 2019-11-28
EP3592355A4 (en) 2021-01-06
RU2019131757A (ru) 2021-04-12
MX387658B (es) 2025-03-18
JP7502863B2 (ja) 2024-06-19
IL269182B1 (en) 2023-07-01
PL3592355T3 (pl) 2026-04-07
CA3055938A1 (en) 2018-09-13
ES3060528T3 (en) 2026-03-26

Similar Documents

Publication Publication Date Title
CY2025027I2 (el) Ελαφιμπρανορη για χρηση στην αντιμετωπιση πρωτοπαθους χολικης χολαγγειτιδας
DK3743053T3 (da) Anvendelse af cannabinoider i behandling af epilepsi
DK3490582T3 (da) Sammensætninger til anvendelse i behandling af myelofibrose
EP3626699A4 (en) SSAO INHIBITOR
DK3592355T3 (da) KX2-391/KX-01 til anvendelse i behandling af aktinisk keratose
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3497086T3 (da) Aminopyrimidin-SSAO-inhibitorer
DK3331915T3 (da) Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3429571T3 (da) Kombinationer af lsd1-hæmmere til anvendelse til behandling af neoplastiske sygdomme
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3806898T3 (da) Gremlin-1-antagonist til anvendelse i behandling af cancer
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3226854T3 (da) Aminosyrebaseret sammensætning til genoprettelse af fibroelastin i hudens bindevæv
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3532067T3 (da) Liposomal formulering til anvendelse til behandling af cancer
DK3044229T3 (da) Peptider til anvendelse i behandlingen af oral mucositis
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
EP3615525C0 (en) PYRROLE DERIVATIVES AS PLK1 INHIBITORS
DK3236983T3 (da) Hidtil ukendt pi3k-gamma-inhibitorpeptid til behandling af sygdomme i åndedrætssystemet
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi